Xeltis, a medtech company developing regenerative vascular implants that transform into living tissue, raised an additional €20.5 million in funding led by Horizon 3 Healthcare, with participation from the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita, and existing investors. Combined with the €50 million secured in 2025, the funding will accelerate clinical development, regulatory milestones, commercial expansion, and manufacturing growth.
Supporting Clinical and Commercial Expansion
The investment will help complete the U.S. pivotal trial of aXess™, prepare for FDA submission and market launch, expand commercialization across Europe, increase manufacturing capacity, and advance the company’s XABG and XPAD vascular implant programs.
“This fundraising not only enables us to bring our groundbreaking vascular access technology to more European patients, as we continue our successful commercial rollout, but also enables us to advance our aXess™ pivotal trial in the US, prepare for US market launch and continue our other exciting clinical programs, XABG and XPAD. We welcome our new investor Horizon 3 Healthcare and thank them, and our existing investors, for their confidence in Xeltis as we look to bring much-needed alternatives to patients.” — Eliane Schutte, Chief Executive Officer, Xeltis
Expanding Regenerative Vascular Technology
The financing follows the European launch of aXess™, including treatment of the first commercial patient in Germany, while the U.S. pivotal trial has surpassed 50% enrollment.
“The data generated by Xeltis to date has been highly compelling and underscores the potential of aXess™ to transform the hemodialysis access landscape and improve patient outcomes. We are impressed by the company’s strong execution and rapid progress and are proud to support Xeltis as it advances aXess™ through US clinical development and European commercialization, while continuing to expand its broader pipeline of transformative implants.” — Matt McNamara, Chief Investment Officer of Horizon 3 Healthcare
“Today’s vascular implants rely on permanent synthetic or biological replacements. Xeltis is pioneering a different approach: enabling implants to gradually transform into the patient’s own living tissue. This shift illustrates how transformative technology is opening new possibilities for patients while reinforcing Europe’s leadership in breakthrough medical innovations. The European Innovation Council is proud to back companies turning this vision into clinical reality.” — Hermann Hauser, Board Member, European Innovation Council (EIC) Fund